Full Circle Capital Corp (FULL) has been named as a Top 25 dividend stock, according the most recent Dividend Channel ''DividendRank'' report. The report noted that among the coverage universe, FULL shares displayed both attractive valuation metrics and strong profitability metrics. For example, the recent FULL share price of $2.50 represents a price-to-book ratio of 0.6 and an annual dividend yield of 16.80% — by comparison, the average company in Dividend Channel's coverage universe yields 4.2% and trades at a price-to-book ratio of 2.1. The report also cited the strong monthly dividend history at Full Circle Capital Corp, and favorable long-term multi-year growth rates in key fundamental data points.The report stated, '' Dividend investors approaching investing from a value standpoint are generally most interested in researching the strongest most profitable companies, that also happen to be trading at an attractive valuation. That's what we aim to find using our proprietary DividendRank formula, which ranks the coverage universe based upon our various criteria for both profitability and valuation, to generate a list of the top most 'interesting' stocks, meant for investors as a source of ideas that merit further research.'' The annualized dividend paid by Full Circle Capital Corp is $0.42/share, currently paid in monthly installments, and its most recent dividend ex-date was on 01/27/2016. Below is a long-term dividend history chart for FULL, which the report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
HOST // Robert Powell
Retirement Planning Event
More from Stocks
With Tilray, You Won't Win Any Valuation Arguments
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Dow Trims Gains on Report China Is Pushing Back During Trade Talks
Stocks rise but come off highs Tuesday on reports that China may be pushing back against American trade talk demands.
Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat
Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.
Jim Cramer: The Ultimate Case for the Leap of Taste not Faith
I think sometimes the best way to parse the temperament is to go over the most obviously "wrong" moves and address why they might not be wrong at all.